0000899243-19-007824.txt : 20190314
0000899243-19-007824.hdr.sgml : 20190314
20190314213133
ACCESSION NUMBER: 0000899243-19-007824
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190313
FILED AS OF DATE: 20190314
DATE AS OF CHANGE: 20190314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WYZGA MICHAEL S
CENTRAL INDEX KEY: 0001201256
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 19682718
MAIL ADDRESS:
STREET 1: RADIUS HEALTH, INC.
STREET 2: 201 BROADWAY, 6TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 955 MASSACHUSETTS AVENUE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 955 MASSACHUSETTS AVENUE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-13
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001201256
WYZGA MICHAEL S
C/O X4 PHARMACEUTICALS, INC.
955 MASSACHUSETTS AVENUE, 4TH FLOOR
CAMBRIDGE
MA
02139
1
0
0
0
Stock Option (right to buy)
10.44
2019-03-13
4
A
0
70324
A
2028-08-21
Common Stock
70324
70324
D
Twenty-five percent (25%) of the shares subject to the option vested on August 22, 2019, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Reflects the Reporting Person's stock option to acquire 740,000 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger").
All share and per share amounts of the Issuer's common stock and stock options reported in this Form 4 reflect the 1-for-6 reverse stock split of the Issuer's common stock effected on March 13, 2019 after the completion of the Merger.
s/ Adam S. Mostafa, attorney-in-fact
2019-03-14